{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:33Z","timestamp":1787847813556,"version":"build-2784847793"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While partial splenic artery embolization (PSE) has been effectively employed in treating portal hypertension, cirrhosis, and idiopathic thrombocytopenia, its combination with hepatic artery infusion chemotherapy (HAIC) for the management of chemotherapy-induced hypersplenism (CIH) has not been previously explored. This retrospective study aims to provide clinical insights into this potential therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective analysis involving patients with colorectal cancer liver metastases (CRLM) who received PSE in conjunction with HAIC (utilizing the FOLFOX regimen) to manage thrombocytopenia due to hypersplenism. Tumor response assessment followed the response evaluation criteria in solid tumors, while adverse reactions were categorized using the Common Terminology Criteria for Adverse Events (version 5.0). The primary objective was to attain a platelet (PLT) count of 100 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L, with secondary objectives encompassing evaluation of adverse events related to the combined therapy and its efficacy against liver metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From January 2018 to May 2023, 20 patients with CRLM and CIH were consecutively enrolled in this investigation, each undergoing PSE and HAIC. In total, PSE was performed 25 times. Median pre- and post-PSE PLT counts were 51 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L and 116 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L, respectively, with 80% of participants reaching the primary endpoint of a PLT count of \u2265100 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Abdominal pain emerged as the most frequent postoperative complication, affecting 11 patients (44%). The objective response rate stood at 25%, while the disease-control rate was reported at 80%. The median progression-free survival was measured at 3.9 months, with a median overall survival of 13.8 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combination of PSE and HAIC (FOLFOX regimen) represents a safe and effective strategy for managing CIH and CRLM, demonstrating favorable outcomes in PLT count restoration and disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_685_25","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:00:14Z","timestamp":1779951614000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combining partial splenic embolization with hepatic artery infusion chemotherapy in the management of chemotherapy-induced hypersplenism in patients with colorectal cancer liver metastases"],"prefix":"10.4103","volume":"22","author":[{"given":"Baojiang","family":"Liu","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qufu Hospital of Traditional Chinese Medicine, Qufu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhai","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxin","family":"Kou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwei","family":"Feng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Cao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzong","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20260528","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.sla.0000243600.98464.a5","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"244","author":"Pulitan\u00f2","year":"2006","journal-title":"Ann Surg"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejso.2007.09.007","article-title":"Effect of preoperative chemotherapy on liver resection for colorectal liver metastases","volume":"34","author":"Mehta","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Overman","year":"2010","journal-title":"J Clin Oncol"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000210025","article-title":"Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer","volume":"76","author":"Angitapalli","year":"2009","journal-title":"Oncology"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/cncr.23432","article-title":"Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy","volume":"112","author":"Kauffman","year":"2008","journal-title":"Cancer"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/000313481708300323","article-title":"Partial splenic artery embolization to treat hypersplenism secondary to hepatic cirrhosis: A meta-analysis","volume":"83","author":"Wang","year":"2017","journal-title":"Am Surg"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00330-015-3839-4","article-title":"Partial splenic embolization for thrombocytopenia in liver cirrhosis: Predictive factors for platelet increment and risk factors for major complications","volume":"26","author":"Cai","year":"2016","journal-title":"Eur Radiol"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2214\/ajr.179.5.1791323","article-title":"Long-term results of initial and repeated partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"179","author":"Kimura","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.engmed.2024.100037","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese College of Interventionalists (CCI)","volume":"1","author":"Zhu","year":"2024","journal-title":"EngMedicine"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00268-009-0095-2","article-title":"Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients","volume":"33","author":"Amin","year":"2009","journal-title":"World J Surg"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdm405","article-title":"Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis","volume":"18","author":"Gallagher","year":"2007","journal-title":"Ann Oncol"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/jso.24399","article-title":"Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies","volume":"114","author":"Cercek","year":"2016","journal-title":"J Surg Oncol"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4103\/jcrt.jcrt_1869_23","article-title":"Combination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study","volume":"21","author":"Hu","year":"2025","journal-title":"J Cancer Res Ther"},{"issue":"Supplement","key":"R19-20260528","first-page":"S761","article-title":"A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32)","volume":"14","author":"Kusano","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0973-1482.184524","article-title":"Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: Jfmc 29-0003","volume":"13","author":"Kusano","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/cam4.856","article-title":"Partial splenic embolization to permit continuation of systemic chemotherapy","volume":"5","author":"Luz","year":"2016","journal-title":"Cancer Med"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/CAD.0000000000000027","article-title":"Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: A preliminary analysis","volume":"25","author":"Chen","year":"2014","journal-title":"Anticancer Drugs"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","article-title":"Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: Comparative results with cisplatin using a rabbit VX2 tumor model","volume":"15","author":"Dzodic","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12876-022-02344-4","article-title":"Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: A real-world retrospective study","volume":"22","author":"Cao","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"1420956","DOI":"10.3389\/fonc.2024.1420956","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy","volume":"14","author":"Zheng","year":"2024","journal-title":"Front Oncol"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"913017","DOI":"10.3389\/fonc.2022.913017","article-title":"A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases","volume":"12","author":"Feng","year":"2022","journal-title":"Front Oncol"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4251\/wjgo.v10.i11.431","article-title":"Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy","volume":"10","author":"Zhang","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): An international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2559.2012.04208.x","article-title":"Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases","volume":"61","author":"Vreuls","year":"2012","journal-title":"Histopathology"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1634\/theoncologist.2009-0152","article-title":"Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver","volume":"14","author":"Cleary","year":"2009","journal-title":"Oncologist"},{"key":"R37-20260528","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s44178-025-00157-5","article-title":"Liver protection of CACA technical guidelines for holistic integrative management of cancer","volume":"4","author":"Zhang","year":"2025","journal-title":"Holist Integr Oncol"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"1288964","DOI":"10.3389\/fphar.2024.1288964","article-title":"Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research","volume":"15","author":"Gong","year":"2024","journal-title":"Front Pharmacol"},{"key":"R39-20260528","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/vox.12146","article-title":"Safety of platelet transfusion: Past, present and future","volume":"107","author":"Katus","year":"2014","journal-title":"Vox Sang"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2214\/ajr.132.5.777","article-title":"Partial splenic embolization in the treatment of hypersplenism","volume":"132","author":"Spigos","year":"1979","journal-title":"AJR Am J Roentgenol"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-3476(94)70261-6","article-title":"Partial splenic embolization in children with hypersplenism","volume":"124","author":"Israel","year":"1994","journal-title":"J Pediatr"},{"key":"R42-20260528","first-page":"1776","article-title":"Clinical application of kelp micro gelation (KMG) in partial splenic embolization","volume":"22","author":"Huang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/13645706.2024.2339917","article-title":"Partial splenic embolization with embosphere microspheres (700-900 mm) for the treatment of hypersplenism: Comparison of selective superior splenic artery embolization and inferior splenic artery embolization","volume":"34","author":"Ma","year":"2025","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1515\/med-2022-0479","article-title":"Repeated partial splenic artery embolization for hypersplenism improves platelet count","volume":"17","author":"Tan","year":"2022","journal-title":"Open Med (Wars)"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042737-200502000-00008","article-title":"Partial splenic embolization in patients with cirrhosis: Efficacy, tolerance and long-term outcome in 32 patients","volume":"17","author":"N'Kontchou","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_685_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:39:23Z","timestamp":1787845163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_685_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_685_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-04-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}